Compass, Inc. Share Price Target ‘$4.15’, now -4.2% Downside Potential

DirectorsTalk Interviews

Compass, Inc. which can be found using ticker (COMP) have now 9 confirmed analysts covering the stock with the consensus suggesting a rating of ‘hold’. The target price High/Low ranges between $6.00 and $3.00 calculating the mean target share price we have $4.15. (at the time of writing). Given that the stocks previous close was at $4.33 this would imply there is a potential downside of -4.2%. It’s also worth noting that there is a 50 day moving average of $3.56 while the 200 day moving average is $3.18. The market cap for the company is 2.13B. The stock price for Affirm Holdings, Inc. is $4.30 USD

The potential market cap would be $2,037,923,773 based on the market consensus.

The company has a dividend yield of 5.95%. Other points of data to note are a P/E ratio of -, revenue per share of $10.46 and a -10.37% return on assets.

Compass, Inc. is a technology-enabled brokerage that provides an end-to-end platform of software, services, and support to helps its residential real estate agents to deliver service to seller and buyer clients. The Company’s platform includes an integrated suite of cloud-based software for customer relationship management, marketing, client service, brokerage services and other critical functionalities, all custom-built for the real estate industry and enables its core brokerage services. The platform also uses data, analytics, artificial intelligence and machine learning to deliver recommendations and outcomes for Compass agents and their clients. Agents use its platform to assist home sellers and buyers in listing, marketing, selling and finding homes, as well as through the provision of services, such as title, escrow and mortgage. Its Glide tools include completion of various real estate forms, offers preparation, as well as e-signature and collaboration capabilities.

Share on:

Latest Company News

Primary Health Properties surplus cash fuels generous dividend, Gervais Williams impressed

Gervais Williams highlights the benefits of long-dated, inflation-linked leases, fixed-rate debt, and synergies from the Assura acquisition, which he believes support resilient earnings, dividend growth, and balance sheet strength despite higher interest rates.

Watches of Switzerland Group upgrades FY26 outlook after strong Q3 performance

Watches of Switzerland Group PLC delivered strong Q3 FY26 performance, with sales growth ahead of expectations across both the US and UK and particularly robust Holiday trading.

Oxford Biomedica expands strategic partnership with Bristol Myers Squibb

Oxford Biomedica has signed a new Commercial Supply Agreement with Bristol Myers Squibb for the manufacture and supply of lentiviral vectors for CAR-T programmes.

SSE Plc Q3 Trading Update: EPS Guidance Maintained

SSE plc reports strong Q3 performance for the nine months to 31 December 2025, with a 64% increase in regulated networks investment and renewable output up 7% year on year.

GSK reports strong 2025 results and reaffirms long-term growth outlook

GSK delivered a strong financial performance in 2025, with sales of £32.7 billion driven by double-digit growth in Specialty Medicines across Respiratory, Immunology & Inflammation, Oncology and HIV.

DCC Plc reports strong Q3 growth and maintains FY outlook

DCC plc reported strong adjusted operating profit growth in the third quarter ended 31 December 2025, driven by good organic performance and the first contribution from recent acquisitions.

    Search

    Search